Trending: Santander to Boost Payouts to Shareholders
1210 GMT - Santander is among the most mentioned companies across news items over the past five hours, according to Factiva data, after the Spanish lender said it would launch a new share buyback program for 1.46 billion euros ($1.57 billion) and said it would increase its 2023 dividend per share by 50%. The eurozone's second-biggest bank by market value is the latest to reward shareholders after UniCredit, BNP Paribas, Deutsche Bank, Societe Generale, BBVA and Banco de Sabadell outlined plans to boost cash returns to shareholders in recent weeks. This comes after Santander's annual net profit hit a record high in 2023 and the bank said it expected higher profitability in 2024, as measured by its return on tangible equity ratio. "We are already seeing good progress in 2024 and expect to achieve all our targets for this year, including a return on tangible equity of 16%," Executive Chair Ana Botin said. European banks could return EUR38 billion through buybacks by the end of the year, coming on top of an expected EUR76 billion in dividends for 2024, Bank of America analysts estimated in a recent research note. Dow Jones & Co. owns Factiva. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 19, 2024 07:25 ET (12:25 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks